I  IndieBio


     Office Locations:

479 Jessie St
San Francisco, CA 94103



  • Seed



  • Life Sciences & Healthcare



    IndieBio is the world's first startup accelerator for synthetic biology. Twice a year, fifteen early stage biology companies move to downtown San Francisco to take part in their intense four-month program. Each team receives seed funding, lab and co-working space, dedicated mentorship, and becomes part of a network of IndieBio alumni, investors, biotech entrepreneurs, investors, press, and corporate partners. The investment is broken into two parts. The first is a share purchase agreement of 8% for taking part in the program and a $250,000 investment (Accelerator Contract for Equity ("ACE") at $3 million dollar valuation cap for a total package valued at $250k ($200k in Cash) in funding.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Alex Kopelyan Program Manager
    Arvind Gupta Managing Director & Founder
    Jun Axup Program Scientist
    Parikshit Sharma Analyst
    Ron Shigeta CSO


    Portfolio companies include:

        web link

      DNALite Therapeutics
        web link

      Finless Foods
        web link

      Health Linkages
        web link

        web link

        web link

      Prellis Biologics
        web link

      Proteorex Therapeutics
        web link

        web link

      Stelvio Therapeutics


    Recent News: